Vivos Therapeutics (NASDAQ: VVOS) has extended its debt conversion agreement with Streeterville Capital, reaffirming its commitment to convert up to $4.5 million in debt into equity.
Key Highlights
• Vivos Therapeutics has extended its debt conversion agreement with Streeterville Capital until August 31, 2026.
• The agreement allows for the conversion of debt into equity, with Streeterville reaffirming its commitment to convert up to $4.5 million.
• Obstructive sleep apnea (OSA) affects nearly 1 billion adults globally, with a significant portion remaining undiagnosed.
• The extended agreement supports Vivos Therapeutics' efforts to bolster its financial position and meet Nasdaq listing requirements.
Debt Restructuring
Vivos Therapeutics (NASDAQ: VVOS) has announced an extension of its debt conversion agreement with Streeterville Capital, as detailed in the New Material Agreement Exhibit 99.1. This extension reaffirms Streeterville’s commitment to convert up to $4.5 million in debt into equity. The move is part of the company’s broader strategy to enhance its financial stability and ensure compliance with Nasdaq listing standards.
Vivos Therapeutics specializes in developing solutions for sleep-related breathing disorders, a growing area of focus in the medical device sector.
Equity Financing
Under the terms of the extended agreement, the company will have the opportunity to restructure its debt obligations into equity instruments. This approach is designed to provide Vivos Therapeutics with greater financial flexibility as it seeks to secure additional capital. The company’s work in sleep apnea treatment has positioned it as a key player in the development of non-invasive therapeutic devices, which have gained attention in the medical community for their potential to address a widespread health concern.
Sleep Apnea Treatment
Obstructive sleep apnea (OSA) remains a major public health issue, impacting nearly 1 billion individuals globally. Many of those affected remain unaware of their condition, highlighting the need for improved diagnostic and treatment options. Vivos Therapeutics has developed proprietary technologies aimed at addressing this gap, offering alternatives to traditional therapies such as continuous positive airway pressure (CPAP) machines.
The company’s innovations reflect broader industry trends toward personalized and patient-friendly medical solutions.
Regulatory Environment
The agreement between Vivos Therapeutics and Streeterville Capital is subject to regulatory oversight, including adherence to Nasdaq’s listing requirements. Maintaining compliance with these standards is critical for the company’s ability to operate on the exchange and attract investor confidence. Vivos Therapeutics continues to navigate the regulatory landscape while advancing its product pipeline, ensuring alignment with industry standards and market expectations.
Market Impact
The extension of the debt conversion agreement is expected to provide Vivos Therapeutics with additional financial resources to support its growth initiatives. The sleep apnea treatment market is characterized by rapid innovation and competition among established and emerging companies. Vivos Therapeutics’ efforts to expand its product offerings and secure financing could strengthen its position in this evolving sector, where demand for effective and accessible treatments continues to rise.
Financial Performance
Vivos Therapeutics’ financial strategy is closely linked to its ability to manage debt and secure equity financing. The extended agreement with Streeterville Capital offers a pathway to improve the company’s balance sheet while pursuing its long-term objectives. Investors will be monitoring the company’s progress in raising capital and executing its business plan, particularly as it relates to scaling operations and expanding market reach in the sleep apnea treatment space.
Investor Insights
The extension of the debt conversion agreement signals a collaborative effort between Vivos Therapeutics and Streeterville Capital to support the company’s financial and operational goals. Investors are likely to view this development as a positive step toward enhancing liquidity and reducing debt burdens. As the company advances its sleep apnea treatment technologies, its ability to meet regulatory and financial milestones will be key factors in shaping investor sentiment and market performance.
The broader sleep apnea treatment industry remains a dynamic and growing field, offering opportunities for companies that can deliver innovative and effective solutions.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.






Please wait processing your request...